Adverum Biotechnologies, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ADVM research report →
Companywww.adverum.com
Adverum Biotechnologies, Inc. , a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema.
- CEO
- Laurent Fischer
- IPO
- 2014
- Employees
- 155
- HQ
- Redwood City, CA, US
Price Chart
Valuation
- Market Cap
- $96.26M
- P/E
- -0.50
- P/S
- 0.00
- P/B
- -1.84
- EV/EBITDA
- -0.77
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -3844.85%
- ROIC
- -619.48%
Growth & Income
- Revenue
- $1.00M · -72.22%
- Net Income
- $-130,927,000 · -7.22%
- EPS
- $-6.62 · -227.72%
- Op Income
- $-139,159,000
- FCF YoY
- -1.24%
Performance & Tape
- 52W High
- $6.07
- 52W Low
- $1.78
- 50D MA
- $4.41
- 200D MA
- $3.48
- Beta
- 0.87
- Avg Volume
- 724.34K
Get TickerSpark's AI analysis on ADVM
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 9, 25 | Fischer Laurent | other | 500,000 |
| Dec 9, 25 | Fischer Laurent | other | 150,000 |
| Dec 9, 25 | Fischer Laurent | other | 25,000 |
| Dec 9, 25 | Fischer Laurent | other | 150,000 |
| Dec 9, 25 | Fischer Laurent | sell | 200,000 |
| Dec 9, 25 | Fischer Laurent | sell | 93,000 |
| Dec 9, 25 | Fischer Laurent | other | 351,513 |
| Dec 9, 25 | Fischer Laurent | other | 522,666 |
| Dec 9, 25 | Fischer Laurent | sell | 110,420 |
| Dec 9, 25 | Soparkar Peter | other | 150,000 |
Our ADVM Coverage
We haven't published any research on ADVM yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ADVM Report →